COVID-19: LMICs need antivirals as well as vaccines.
COVID-19: LMICs need antivirals as well as vaccines.
复制标题
COVID-19：中低收入国家需要抗病毒药物和疫苗。
DOI：
10.1038/d41586-022-00220-5
复制
发表时间：
2022
期刊：
影响因子：
64.8
通讯作者：
Stanford,FatimaCody
中科院分区：
文献类型：
--
作者：
Bajaj,SimarSingh;Stanford,FatimaCody
在与新冠肺炎的战斗中，必须在莫努皮拉韦和尼马瑞韦等抗病毒药物的分销方面实现全球公平。这些是有效的公共卫生工具，超越了疾病缓解和疫苗接种(例如，见《自然》杂志601,165；2022)。这些药丸价格便宜，使用方便，非常适合低收入和中等收入国家(LMIC)。在疫苗接种不足的LMIC，广泛获得抗病毒药物至关重要。与疫苗和单抗相比，抗病毒药物可能是对抗新出现的SARS-CoV-2变种的更持久的防御措施。它们有可能在全球范围内防止数十万人住院和死亡。然而，LMIC目前面临着重大的制造和定价障碍，高收入国家购买了现有供应的大部分(见GO)。大自然。Com/3nfz)。
In the battle against COVID-19, there must be global equity in the distribution of antiviral drugs such as molnupiravir and nirmatrelvir. These are potent public-health tools beyond disease mitigation and vaccination (see, for example, Nature 601, 165; 2022). Cheap and easy to use, these pills are well suited to low-and middle-income countries (LMICs).In under-vaccinated LMICs, widespread access to antiviral drugs is crucial. Antivirals could be a more enduring defence against emerging SARS-CoV-2 variants than are vaccines and monoclonal antibodies. They have the potential to prevent hundreds of thousands of hospitalizations and deaths globally. However, LMICs currently face significant manufacturing and pricing obstacles, and high-income countries have bought much of the existing supply (see go. nature. com/3nfz).